Immix Biopharma, Inc.
Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for light chain (AL) amyloidosis and other serious diseases. Its lead candidate, NXC-201, is an autologous CAR-T therapy targeting BCMA and is being evaluated in U.S. and ex-U.S. clinical trials for relapsed or… From the company’s description.
In fiscal 2025, Immix Biopharma, Inc. reported a net loss of $29.44M. Operations used $23.93M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Immix Biopharma, Inc. does
In the company’s own words
Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for light chain (AL) amyloidosis and other serious diseases. Its lead candidate, NXC-201, is an autologous CAR-T therapy targeting BCMA and is being evaluated in U.S. and ex-U.S. clinical trials for relapsed or refractory AL amyloidosis. The company also pursues NXC-201 in other indications and additional preclinical candidates using its N-GENIUS platform, which includes EXPAND cell-engineering technology and a binding-scaffold generation engine. Its NEXICART-2 U.S. trial is designed to enroll 40 patients; the company plans to use its results to support a potential biologics license application. Immix relies on third-party contract manufacturers for clinical-stage product supply and conducts research and development through subsidiaries, including operations in Australia. The business is focused on research and development, with no reportable segments described. Its website is https://immixbio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- LOS ANGELES, CA
- Fiscal year end
- December
- CIK
- 1873835
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Immix Biopharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Immix Biopharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Immix Biopharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Immix Biopharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Immix Biopharma, Inc.'s last four quarterly filings that the numbers alone won't show?”